# 바이오스페이스 일일 뉴스 리포트 - 2025년 09월 09일


## 주요 헤드라인

1. **Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/alkermes-one-ups-takeda-in-narcolepsy-clearing-cognitive-impairments-in-mid-stage-trial>

2. **Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/alkermes-one-ups-takeda-in-narcolepsy-clearing-cognitive-impairments-in-mid-stage-trial>

3. **FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/fda-demurs-on-glp-1-compounding-fight-debuts-consumer-green-list-instead>

4. **FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/fda-demurs-on-glp-1-compounding-fight-debuts-consumer-green-list-instead>

5. **Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/rapport-jumps-180-on-best-case-mid-stage-data-for-epilepsy-pill>

6. **Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/summits-keytruda-challenger-hits-cross-country-consistency-problems-raising-us-approval-questions>

7. **Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/servier-bets-450m-on-kaerus-fragile-x-syndrome-therapy>


---
*2025년 09월 09일 바이오스페이스 뉴스 피드에서 생성된 리포트*